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Objective: To evaluate the retail sales of pressurised metered-dose inhalers (pMDIs),
dry-powder inhalers (DPIs) and liquids for nebulisation in 16 European countries.
Methods: Retail sales data relating to pMDIs, DPIs and liquids for nebulisation delivering short-
and long-acting bronchodilators, corticosteroids and combinations between 2002 and 2008
were obtained from the IMS sales database. The IMS database ensured that wholesalers’ stock
sales accurately matched that of retail pharmacies and included purchases by panelof Internal Medicine, Section of Immunoallergology, Respiratory Diseases and Cell Therapy, University
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1100 F. Lavorini et al.pharmacies directly from pharmaceutical manufacturers, specialist wholesalers and distribu-
tion cooperatives.
Results: Mean inhaler retail sales (expressed as percentages of total sales) were 47.5% for
pMDIs, 39.5% for DPIs and 13% for nebulisers. The distribution of inhaler sales differed signif-
icantly between the countries with pMDI sales greatest in the United Kingdom and Hungary
compared to other countries, where DPI sales prevailed. Sales of nebulisation liquids were high
in Italy. The pMDI was the most frequently prescribed inhaler for bronchodilators. In contrast,
retail sales of DPIs were similar to those of pMDIs for inhaled corticosteroids, and higher in the
case of inhalers with combined long-acting b2-agonist and corticosteroid.
Conclusion: We found a high degree of variability in inhaler prescription between European
countries. Differing health policies, costs, health insurance issues, pharmaceutical/commer-
cial aspects and prescribers’ and patients’ preferences may explain this variation. We suggest
a need for more uniform, outcome-led inhaler prescribing practice across Europe to improve
the efficacy and cost effectiveness of the treatment of obstructive airways diseases.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
There are more than 230 different deviceedrug combina-
tions available in Europe1 for inhaled therapy of respira-
tory conditions, particularly asthma and chronic
obstructive pulmonary disease (COPD). Although variety
helps with finding an inhaler to suit every patient, for
prescribers it complicates choosing a device and keeping
abreast of what is available and how to use it. Incorrect
inhaler usage may partly explain why many treated
patients continue to report symptoms. Inhaler misuse is
extremely common2e4 and may partly explain why many
patients treated with potentially effective inhaled therapy
continue to report symptoms.5,6 Marketed inhalation
devices can be broadly classified as pressurised metered-
dose inhalers (pMDIs), dry-powder inhalers (DPIs) and
liquids for nebulisation. The efficiency with which these
devices deliver inhaled medications to the lower respira-
tory tract is influenced by a multitude of factors, including
their design and characteristics, the formulation (i.e.
solution, suspension) of the contained medication, the
particle size and velocity of the aerosol produced and the
ease with which patients can perform the required critical
steps to use them properly.7 In addition, even with correct
inhalation technique, lung deposition for different inhaler
devices varies greatly from 4% for beclometasone deliv-
ered by chlorofluorocarbon-propellant MDIs to 53% for
extra-fine beclometasone delivered by CFC-free hydro-
flouroalkane-propellant pMDIs.8 Patient preference is
important because it may influence adherence to treat-
ment.7 It is clearly pointless to prescribe an inhaler device
which the patient will not, or cannot use correctly. Thus,
choosing the correct inhaler for each patient is just as
important as choosing the most appropriate medication.
Prescribing is a major element of the delivery of primary
healthcare and prescribing practice varies considerably
across Europe9 at many levels, from the organisation of
national health services to the environment and expertise
of individual prescribers.10 Many other influences such as
demography, morbidity and practice policies have been
shown to influence prescribing habits.10 In some countries,
primary care prescribing is led primarily by cost.11 Phar-
maco-epidemiological analysis is difficult when single drugsare used for a wide variety of indications; however, inhaled
medications are mainly used for a limited and relatively
well defined set of indications, (asthma and COPD)
according to management guidelines which are broadly
uniform across Europe, making comparison feasible.
To investigate how far national prescribing practice for
inhaled drugs varies across Europe, we assessed European
retail sales data for inhaled medications delivered by
pMDIs, DPIs, and liquids for nebulisation commonly used for
the treatment of asthma and COPD.
Methods
Data source
We retrospectively evaluated in 16 European countries
retail sales of short-acting b-adrenergic (SABA) and anti-
muscarinic (SAMA) bronchodilators, long-acting b-adren-
ergic (LABA) and anti-muscarinic (LAMA) bronchodilators,
inhaled corticosteroids (ICS) alone and fixed combinations
of LABA with ICS using the IMS Health databases.12 Retail
sales of inhalers delivering sodium cromoglycate and
nedocromil sodium were not evaluated. IMS is an interna-
tional healthcare information company specialising in the
collection and interpretation of anonymised health infor-
mation, and often the only source of information on
aspects of medicine utilisation across the world.12 Its
databases represent an invaluable source for pharmaco-
epidemiological studies. For the present study, we used the
IMS DPM audit (database) covering inhaler sales data for 7
years (2002e2008) in Austria, Belgium, Denmark, Finland,
France, Germany, Hungary, Italy, Netherlands, Norway,
Poland, Portugal, Spain, Sweden, Switzerland and United
Kingdom. For each country, the data included supplies
by all wholesalers as well as those directly supplied by
manufactures to a representative panel of approximately
4000 pharmacies.12
Data analysis
Annual inhaler retail sales of inhaler units by country over
the 7 years were averaged and expressed as percentages of
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defined as a single inhaler; for liquids, a unit was defined as
a single package of nebuliser solution. Differences in total
retail sales between countries were assessed using the chi-
squared test and analysis of standardised residuals.
Differences between pMDIs, DPIs, and liquids sales were
assessed using analysis of variance followed by Dunn’s
multiple comparison test. Since LABA and LABA þ ICS are
not available as liquids, sales of pMDIs delivering these
drugs were compared using Student’s t-test. In all cases,
P < 0.05 was considered as significant.Figure 1 Panel A: Total units sold over the time period 2002e2
percentages of the total sales, in 16 European countries over the ti
DK, Denmark; E, Spain; F, France; FL, Finland; H, Hungary; I, Italy;
Poland; S, Sweden; UK, United Kingdom. Panel C: Mean (SD) retail
(SABA) and anti-muscarinic (SAMA) bronchodilators, long-acting b
inhaled corticosteroids (ICS) and combination of LABA þ ICS expre
period 2002e2008. pMDIs, pressurised metered-dose inhalers; DPIsResults
During this 7-year period, the total number of pMDI and DPI
units sold were significantly (P < 0.01) higher than those of
liquids for nebulisers (47,5%, 39,5% and 13% of the total units
sold, respectively, Fig. 1A). The distribution of units sold
significantly (P< 0.01) differed between the countries, with
pMDI retail sales greatest in the United Kingdomand Hungary
compared to the other countries in which retail sales of DPIs
prevailed (Fig. 1B). The sale of liquids for nebulisation was
significantly (P < 0.01) higher in Italy (Fig. 1B) than in the008. Panel B: Retail sales of inhalation devices, expressed as
me period 2002e2008. A, Austria; B, Belgium; CH, Switzerland;
D, Germany; N, Norway; NL, The Netherlands; P, Portugal; PL,
sales of inhalation devices delivering short-acting b-adrenergic
-adrenergic (LABA) and anti-muscaric (LAMA) bronchodilators,
ssed as percentages of the total retail sales, during the time
dry-powder inhalers. ), P < 0.05; )), P < 0.01.
1102 F. Lavorini et al.other countries. Dividing sales by type of medication, pMDIs
were most frequently (P < 0.01) prescribed for bronchodi-
lators, pMDIs and DPIs were prescribed with an approxi-
mately equal frequency for ICS alone while fixed
combinations of LABA þ ICS were much more frequently
(P< 0.01) prescribedas DPIs than pMDIs (Fig. 1C). Repartition
of devices delivering specific inhaledmedications (i.e. SABA,
SAMA, LABA, LAMA, ICS and fixed combination of LABA plus
ICS) across European countries is reported in Fig. 2.Discussion
With rare exceptions (for example in cases of emergency)
inhaler sales in Europe result from doctors prescriptions.
Assuming that inhaled therapy is prescribed for asthma and
COPD according to roughly concordant national guidelines
across Europe, with inhaler prescriptions matched to indi-
vidual patient needs and ability, it follows that these should
be roughly equivalent across Europe. Our findings, however,
demonstrate this is not the case. The pMDI is widely
prescribed in Europe, most likely because of its low cost and
widespread availability of medications delivered by such
inhaler. This is paradoxical when one considers that this
device is often used incorrectly by patients.2 A series of
studies performed by Crompton et al.13e15 and others,2,16
suggested that only about 20% of patients use a pMDI
correctly after simply reading the package insert, while only
just over 50% are able to do so even after specific instruction.
These data raise concern that local prescribing may not be
influenced primarily by the ability of the patient to use the
prescribed device, but by other factors such as cost,
marketing strategies and prescribers’ and patients’ biases.
The choice of the device is also influenced by the knowledge
and ability of the prescriber to use the device. It has been
shown about 50% of respiratory nurses, medical doctors andFigure 2 Repartition across European countries of inhalation dev
LABA þ ICS expressed as percentages of the total retail sales overrespiratory therapists were unable to use inhalation devices
correctly.17e19 Various explanations may account for this
such as lack of familiarity with specific devices, inadequate
time to teach, poor training techniques, poor training
materials, all influencing prescribers choice.
The reasons underlying the relatively high sales of devices
delivering SABA/SAMA in some countries are unknown. These
may reflect poor disease control in those populations;
however, thismay also reflect prescribing patterns in keeping
with locally used asthma/COPD self management plans.
Despite the overall predominance of pMDI sales, DPIs sales
are high in many European countries and sales of inhaled
liquids for nebulisation particularly in Italy (approximately
45% of the total Italian sales). The latter findingmight reflect
high prescriptions of nebulised corticosteroids (see Fig. 2,
panel B), likely for acute respiratory illnesses other than
asthma or COPD, particularly in children.20
There are some obvious limitations when interpreting the
data in the present study. The figures take no account of
possible differences in the prevalence of asthma and COPD
and the characteristics (i.e. age, severity of the disease) of
affected patients in European countries, or the possibility
that some of the prescribing was for diseases other than
asthma or COPD. In addition, retail sales do not necessarily
equate to individual patient prescriptions; however, due to
the nature of the database used in the present study, it was
not possible to accurately estimate daily defined dosages for
the different device/drug combinations. This is clearly
a subject for future research if we are to learn from the
different approaches throughout Europe.
The nature of the IMS database analysed for this study
did not allow us to differentiate between sales of breath-
actuated and simple pMDIs. This may be a topic for further
study, particularly, if these differences could be related to
asthma outcomes. Despite these limitations, we believe
this study is of interest in highlighting the variability inices delivering SABA/SAMA, LABA/LAMA, ICS and combination of
the time period 2002e2008. See Fig. 1 for abbreviations.
Inhaler sales in Europe 1103inhaler prescribing practice across Europe and the
dichotomy between the relative proportions of devices
prescribed and those most likely to be used properly. The
data suggest a need for more uniform, outcome-led inhaler
prescribing practice across Europe, and for better educa-
tion about the advantages and limitations of specific
devices for prescribers and patients in order to improve the
efficacy and cost effectiveness of the treatment of
obstructive airways diseases. Perhaps, this improvement
could be achieved through more attention by guideline
developers to implementation of guidelines.Conflict of interest statement
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